[EN] alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I<br/>[FR] MODULATEURS DU RÉCEPTEUR Alpha7 NICOTINIQUE D'ACÉTYLCHOLINE ET LEURS UTILISATIONS
申请人:BIONOMICS LTD
公开号:WO2014019023A1
公开(公告)日:2014-02-06
The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I
申请人:Merck Sharp & Dohme Corp.
公开号:US20150175534A1
公开(公告)日:2015-06-25
The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.
alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF
申请人:Merck Sharp & Dohme Corp.
公开号:EP2888229B1
公开(公告)日:2019-02-06
alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
申请人:Merck Sharp & Dohme Corp.
公开号:EP2888229A1
公开(公告)日:2015-07-01
ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I
申请人:MERCK SHARP & DOHME CORP.
公开号:US20170158628A1
公开(公告)日:2017-06-08
The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of α7 nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also neuropathic pain and inflammatory diseases.